Download file to see previous pages...
A number of healthcare programs have come to the aid of ESRD patients in the United States, among them Medicaid, Medicare, and private insurance (Sullivan 47). Through these programs, it is evident that healthcare provision is an expensive undertaking. As healthcare costs in this line exacerbates, the different forms of ESRD treatment do not seem to have a significant difference in terms of costs. Hemodialysis and Peritoneal dialysis exhibit significant differences in the mode of treatment employed, but the costs incurred are roughly the same. This implies that the choice on the mode of treatment to use on patients remains a critical decision that nephrologists have to make.
Another critical aspect to capture in addressing ESRD concerns is reimbursement. Despite the relative treatment differences in hemodialysis and peritoneal dialysis (CAPD and CCPG), the reimbursement structure is the same (Sullivan 49). The government, through its various healthcare programs, and insurance companies continue to direct funds and resources to the coverage of qualifying patients and subscribers respectively. The reimbursement structuring has remained relatively the same, characterized by an ever rising trend in healthcare costs. Both nephrologists and ESRD patients have had substantial decisions to make regarding the reimbursement structure and the various treatment options available.
There are a number of economic concerns that revolve around ESRD patients and their daily lives. To start with, these patients can hardly maintain permanent employment, meaning that their income earning continuity is relatively curtailed. This translates to a financial challenge to the patient and his/her dependents if any. Secondly, government healthcare programs and insurance companies do not necessarily provide 100% coverage. This means that the patients have additional costs to meet, especially in terms of acquiring ancillary drugs. Resulting to dialysis or kidney
...Download file to see next pagesRead More
End-stage renal disease (ESRD), sometimes known as chronic kidney disease, or kidney failure is one of these chronic diseases. This paper shall be a case study about Donna, an ESRD patient. First, this paper shall define and describe ESRD; second, it shall discuss the experience of the patient in relation to her chronic condition, comparing this to the typical lived experience of those with this condition; third, an outline of differences in the perceptions held by the patient and their family members concerning the disease shall be compared with the general community; lastly, it shall discuss what self-management education the patient requires, as well as the discharge plan and community re
Chronic kidney disease (CKD) and cardiovascular disease (CVD) are usually associated with causing mortality risk, studies show that cardiovascular risk increase if the patient suffers from anemia (Fishbane, 2005, p.716). Cardiovascular disease is normally associated with the renal disease, while chronic kidney disease enhances hypertension and dyslipidemia, which leads to renal failure.
To achieve the above objective, I have arranged my paper into four sections, of which two of the sections have sub sections. In the first section, I will look at how the body operates normally in the absence of the disease, in the second section, I will look into the abnormal state or, in the presence of the disease and on its subsection I will look into the signs and symptoms of the disease, its causes, its diagnosis, then in the third section, I will look into its potential way of treatment, and on its subsection I will consider looking into two ways of treating it that is Dialysis, Kidney transplantation, on same subsection I will look into the negative side effects of each of the treatme
This condition results in acute failure like injuries, accidents, or in some situations surgeries complications causing the kidney to be deprived of its normal blood flow. In addition to these internal effects of the acute renal failure to the patients, there are external effects of the disease which have proved to be even more difficult to deal with.
Hence, since 1972, the American Healthcare system has ensured that ENDR patients are eligible for the public health Medicare program regardless of any other factors. This has meant there is a substantially
The presence of abnormal plasma levels in multiple substances is remarkably consistent. Some of those substances include parathyroid gland and urea. These are classified as uremic toxic substances. Clinical signs of the end stage renal
However, the advancement in technology allows for lives to be prolonged (Moon, 2006). This is through treatment that may look for alternative means for the body to cope without its filtration system. Nowadays, there are facilities that take care of patients with